Stenocare A/S (CPH:STENO)
Denmark · Delayed Price · Currency is DKK 0.9380
+0.0020 (0.21%)
Aug 18, 2026, 9:53 AM CET
Stenocare Earnings Call Transcripts
Fiscal Year 2024
-
Transitioning to a trading company, focusing on high-growth markets and launching the patented Astrum product. Cost reductions, improved equity ratio, and a planned capital raise address recent sales declines and liquidity needs. Permanent legalization in Denmark expected to boost demand.
-
Plans include doubling sales and reaching break even in 2024, supported by new product launches and entry into the Canadian market with the innovative Astrum oil. The ongoing TO2 warrant exercise funds expansion, product approvals, and facility upgrades.